Robbert J De Winter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4164616/publications.pdf

Version: 2024-02-01

142 papers 3,669 citations

32 h-index 54 g-index

145 all docs

145 docs citations

145 times ranked 5358 citing authors

#	Article	IF	CITATIONS
1	Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. European Journal of Preventive Cardiology, 2022, 29, 312-320.	1.8	6
2	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization inÂPatientsÂWithÂHeavyÂCalcification. JACC: Cardiovascular Interventions, 2022, 15, 193-204.	2.9	23
3	Prognostic Value of Pulmonary Hypertension, Right Ventricular Function and Tricuspid Regurgitation on Mortality After Transcatheter Mitral Valve Repair: AÂSystematic Review and Meta-Analysis. Heart Lung and Circulation, 2022, 31, 696-704.	0.4	2
4	Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease. Journal of Cardiovascular Computed Tomography, 2022, 16, 336-342.	1.3	5
5	Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy. Scientific Reports, 2022, 12, 5521.	3.3	8
6	Optimal Medical Therapy Prescription in Patients with Acute Coronary Syndrome in the Netherlands: A Multicenter Pilot Registry. American Journal of Cardiovascular Drugs, 2021, 21, 219-229.	2.2	9
7	Usefulness of updated logistic clinical SYNTAX score based on MIâ€SYNTAX score in patients with STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 97, E919-E928.	1.7	4
8	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq0 0 0 rgl	BT 10 0verlo	ockal 0 Tf 50 4!
9	Review of Digitalized Patient Education in Cardiology: A Future Ahead?. Cardiology, 2021, 146, 263-271.	1.4	17
10	Online Quantitative Aortographic Assessment of Aortic Regurgitation AfterÂTAVR. JACC: Cardiovascular Interventions, 2021, 14, 531-538.	2.9	8
11	Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis. Circulation: Cardiovascular Imaging, 2021, 14, e011688.	2.6	O
12	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation, 2021, 144, 96-109.	1.6	41
13	Ten-year all-cause mortality following staged percutaneous revascularization in patients with complex coronary artery disease. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
14	Pre-Operative Plasma Extracellular Vesicle Proteins are Associated with a High Risk of Long Term Secondary Major Cardiovascular Events in Patients Undergoing Carotid Endarterectomy. European Journal of Vascular and Endovascular Surgery, 2021, 62, 705-715.	1.5	5
15	Closing a Right Coronary Artery Fistula Draining Into the Coronary Sinus Using a Covered Stent in the Coronary Sinus. JACC: Case Reports, 2021, 3, 1589-1593.	0.6	1
16	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	1.7	4
17	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. International Journal of Cardiology, 2020, 300, 93-98.	1.7	4
18	An initial exploration of subtraction electrocardiography to detect myocardial ischemia in the prehospital setting. Annals of Noninvasive Electrocardiology, 2020, 25, e12722.	1.1	9

#	Article	IF	CITATIONS
19	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	0
20	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
21	Ten-year outcomes of an early invasive or a selective invasive strategy in non-ST-segment elevation acute coronary syndrome patients with and without diabetes mellitus: a subgroup analysis of the ICTUS trial. Coronary Artery Disease, 2020, 31, 95-97.	0.7	1
22	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology, 2020, 320, 27-34.	1.7	4
23	Plasma extracellular vesicle proteins are associated with stress-induced myocardial ischemia in women presenting with chest pain. Scientific Reports, 2020, 10, 12257.	3.3	16
24	Threeâ€year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€eluting stent in routine PCI in patients with diabetes mellitus— AIDA subâ€study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	1.7	1
25	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	3.9	15
26	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. Expert Opinion on Drug Delivery, 2020, 17, 931-945.	5.0	6
27	Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2020, 13, e008737.	3.9	17
28	MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart, 2020, 7, e001223.	2.3	45
29	Estimation of Intraglomerular Pressure Using Invasive Renal Arterial Pressure and Flow Velocity Measurements in Humans. Journal of the American Society of Nephrology: JASN, 2020, 31, 1905-1914.	6.1	7
30	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thrombosis and Haemostasis, 2020, 120, 1087-1095.	3.4	14
31	Quantitative Assessment of Acute Regurgitation Following TAVR. JACC: Cardiovascular Interventions, 2020, 13, 1303-1311.	2.9	23
32	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
33	Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect. European Heart Journal Cardiovascular Imaging, 2019, 20, 225-232.	1.2	9
34	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
35	Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology, 2019, 143, 62-72.	1.4	32
36	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23

#	Article	IF	Citations
37	Medium-term systemic blood pressure after stenting of aortic coarctation: a systematic review and meta-analysis. Heart, 2019, 105, 1464-1470.	2.9	15
38	ABSORB IV: will the low rate of scaffold thrombosis persist?. Lancet, The, 2019, 393, 2392.	13.7	1
39	Aortic Root Geometric and Dynamic Changes After Device Closure of Interatrial Shunts. Journal of the American Society of Echocardiography, 2019, 32, 1016-1026.e5.	2.8	3
40	Impact of atrial septal defect closure on diffusing capacity for nitric oxide and carbon monoxide. ERJ Open Research, 2019, 5, 00260-2018.	2.6	1
41	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
42	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
43	Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS. Data in Brief, 2019, 27, 104750.	1.0	10
44	Threeâ€year clinical outcomes after dualâ€therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	1.7	8
45	High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome. Circulation, 2019, 139, 134-136.	1.6	26
46	Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease. European Journal of Heart Failure, 2019, 21, 249-251.	7.1	0
47	Impact of Coronary Remodeling on Fractional Flow Reserve. Circulation, 2018, 137, 747-749.	1.6	20
48	Does the novel delivery system for the STENTYS self-apposing coronary stent increase the risk of stent edge dissections? Optical coherence tomography post stent findings. Expert Review of Medical Devices, 2018, 15, 157-165.	2.8	3
49	Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. Cardiovascular Revascularization Medicine, 2018, 19, 373-375.	0.8	3
50	Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. Catheterization and Cardiovascular Interventions, 2018, 92, E106-E114.	1.7	6
51	Comparison of Outcomes of Transfemoral Aortic Valve Implantation in Patients <90 With Those >90 Years of Age. American Journal of Cardiology, 2018, 121, 1581-1586.	1.6	18
52	Differences in rotational positioning and subsequent distal main branch rewiring of the Tryton stent: An optical coherence tomography and computational study. Catheterization and Cardiovascular Interventions, 2018, 92, 897-906.	1.7	5
53	Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial. European Heart Journal Cardiovascular Imaging, 2018, 19, 59-66.	1.2	21
54	Visual estimation versus different quantitative coronary angiography methods to assess lesion severity in bifurcation lesions. Catheterization and Cardiovascular Interventions, 2018, 91, 1263-1270.	1.7	10

#	Article	IF	CITATIONS
55	Fiveâ€year followâ€up of the endothelial progenitor cell capturing stent versus the paxlitaxelâ€eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheterization and Cardiovascular Interventions, 2018, 91, 1212-1218.	1.7	4
56	A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet, The, 2018, 391, 431-440.	13.7	70
57	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the TreatmentÂof Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	2.9	88
58	Use of Pulmonary Inhalants Remains Remarkably High After Atrial Septal Defect Closure. Circulation Journal, 2018, 82, 2913-2916.	1.6	0
59	Atrial septal defect in adults is associated with airway hyperresponsiveness. Congenital Heart Disease, 2018, 13, 959-966.	0.2	6
60	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	2.9	21
61	Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. Open Heart, 2018, 5, e000833.	2.3	7
62	Guideline-defined futility or patient-reported outcomes to assess treatment success after TAVI: what to use? Results from a prospective cohort study with long-term follow-up. Open Heart, 2018, 5, e000879.	2.3	21
63	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. European Heart Journal, 2018, 39, 4101-4108.	2.2	89
64	Cardiac diagnostic work-up of ischaemic stroke. European Heart Journal, 2018, 39, 1851-1860.	2.2	25
65	Infective Endocarditis After Melody Valve Implantation in the Pulmonary Position: A Systematic Review. Journal of the American Heart Association, $2018, 7, .$	3.7	62
66	The STENTYS self-apposing stent technology in coronary artery disease: literature review and future directions. Expert Review of Medical Devices, 2018, 15, 479-487.	2.8	5
67	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. European Heart Journal, 2018, 39, 3314-3321.	2.2	116
68	Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stent. Minerva Cardiology and Angiology, 2018, 66, 262-272.	0.7	2
69	A simplified and reproducible method to size the mitral annulus: implications for transcatheter mitral valve replacement. European Heart Journal Cardiovascular Imaging, 2017, 18, jew132.	1.2	17
70	The REMEDEE-OCT Study. JACC: Cardiovascular Interventions, 2017, 10, 489-499.	2.9	35
71	Angiographic assessment of aortic regurgitation by videoâ€densitometry in the setting of TAVI: Echocardiographic and clinical correlates. Catheterization and Cardiovascular Interventions, 2017, 90, 650-659.	1.7	27
72	Early Invasive Versus Selective Strategy forÂNon–ST-Segment Elevation AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2017, 69, 1883-1893.	2.8	29

#	Article	IF	Citations
73	Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?. Expert Review of Medical Devices, 2017, 14, 325-334.	2.8	8
74	What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2017, 50, 952-959.	0.9	6
75	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	31
76	Hemodynamic Measurements forÂtheÂSelection of Patients With RenalÂArteryÂStenosis. JACC: Cardiovascular Interventions, 2017, 10, 973-985.	2.9	18
77	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2017, 38, 2559-2566.	2.2	42
78	Prevalence, predictors, and prognostic implications of residual impairment of functional capacity after transcatheter aortic valve implantation. Clinical Research in Cardiology, 2017, 106, 752-759.	3.3	17
79	Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. International Journal of Cardiovascular Imaging, 2017, 33, 431-439.	1.5	11
80	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	7
81	J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets. Circulation, 2017, 136, 2220-2229.	1.6	42
82	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart, 2017, 4, e000634.	2.3	13
83	Predicting hospitalisation duration after transcatheter aortic valve implantation. Open Heart, 2017, 4, e000549.	2.3	10
84	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	2.8	95
85	Efficacy of the RADPAD Protection Drape in Reducing Operators' Radiation Exposure in the Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	48
86	Anxiety levels of patients undergoing coronary procedures in the catheterization laboratory. International Journal of Cardiology, 2017, 228, 926-930.	1.7	55
87	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. International Journal of Cardiology, 2017, 226, 60-64.	1.7	20
88	Transcatheter closure of an iatrogenic aorta-right ventricular fistula after transfemoral aortic valve implantation. European Heart Journal - Case Reports, 2017, 1, ytx019.	0.6	2
89	First generation versus second generation drugâ€eluting stents for the treatment of bifurcations: 5â€year followâ€up of the <scp>LEADERS</scp> allâ€comers randomized trial. Catheterization and Cardiovascular Interventions, 2016, 87, E248-60.	1.7	44
90	The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the) Tj ETQqC Interventions, 2016, 9, .	0 0 rgBT 3.9	/Overlock 10 1 15

Interventions, 2016, 9, .

#	Article	IF	CITATIONS
91	Historical developments of atrial septal defect closure devices: what we learn from the past. Expert Review of Medical Devices, 2016, 13, 555-568.	2.8	35
92	Individual Long-Term Mortality PredictionÂFollowing Either Coronary Stenting orÂBypass Surgery in PatientsÂWith Multivessel and/or Unprotected Left MainÂDisease. JACC: Cardiovascular Interventions, 2016, 9, 1564-1572.	2.9	45
93	A granular approach to improve reproducibility of the echocardiographic assessment of paravalvular regurgitation after TAVI. International Journal of Cardiovascular Imaging, 2016, 32, 1519-1527.	1.5	6
94	The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease. Expert Opinion on Drug Delivery, 2016, 13, 1489-1499.	5.0	11
95	Time dependent apoptotic rates in the evolving coronary thrombus mass of myocardial infarction patients. Thrombosis Research, 2016, 145, 12-17.	1.7	5
96	Long-term effect of stents eluting 6-mercaptopurine in porcine coronary arteries. Journal of Negative Results in BioMedicine, 2016, 15, 20.	1.4	3
97	The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent. European Heart Journal Quality of Care & Dutcomes, 2016. 2. 108-116.	4.0	3
98	Acute Gain in Minimal Lumen AreaÂFollowing Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds orÂXience Metallic Stents. JACC: Cardiovascular Interventions, 2016, 9, 1216-1227.	2.9	18
99	1-Year Results of the REMEDEEÂRegistry. JACC: Cardiovascular Interventions, 2016, 9, 1127-1134.	2.9	45
100	Reduced acute myocardial ischemia–reperfusion injury in IL-6-deficient mice employing a closed-chest model. Inflammation Research, 2016, 65, 489-499.	4.0	52
101	Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. International Journal of Cardiovascular Imaging, 2016, 32, 871-883.	1.5	35
102	The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. JACC: Cardiovascular Interventions, 2016, 9, 1231-1242.	2.9	80
103	Echocardiographic and angiographic assessment of paravalvular regurgitation after TAVI: optimizing inter-technique reproducibility. European Heart Journal Cardiovascular Imaging, 2016, 17, 852-860.	1.2	22
104	Older coronary thrombus is an independent predictor of $1\hat{a} \in \mathbf{y}$ ear mortality in acute myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 501-510.	3.4	11
105	Bioresorbable drug-eluting scaffolds for treatment of vascular disease. Expert Opinion on Drug Delivery, 2016, 13, 725-739.	5.0	3
106	Ventricular arrhythmia burst is an independent indicator of larger infarct size even in optimal reperfusion in STEMI. Journal of Electrocardiology, 2016, 49, 345-352.	0.9	8
107	Granulocytes in coronary thrombus evolution after myocardial infarction â€" time-dependent changes in expression of matrix metalloproteinases. Cardiovascular Pathology, 2016, 25, 40-46.	1.6	18
108	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. Journal of Thrombosis and Thrombolysis, 2016, 41, 441-451.	2.1	9

#	Article	IF	CITATIONS
109	Effects of renal sympathetic denervation on cardiac sympathetic activity and function in patients with therapy resistant hypertension. International Journal of Cardiology, 2016, 202, 609-614.	1.7	13
110	Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling. Scientific Reports, 2015, 5, 15404.	3.3	33
111	Impact of the Orbital Atherectomy SystemÂon a Peripheral Calcified Lesion. JACC: Cardiovascular Interventions, 2015, 8, e205-e206.	2.9	5
112	Comparison between two―and threeâ€dimensional quantitative coronary angiography bifurcation analyses for the assessment of bifurcation lesions: A subanalysis of the TRYTON pivotal IDE coronary bifurcation trial. Catheterization and Cardiovascular Interventions, 2015, 86, E140-9.	1.7	9
113	Prospective evaluation of where reperfusion ventricular arrhythmia "bursts―fit into optimal reperfusion in STEMI. International Journal of Cardiology, 2015, 195, 136-142.	1.7	9
114	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2015, 184, 128-134.	1.7	15
115	Cardiorenal axis and arrhythmias: Will renal sympathetic denervation provide additive value to the therapeutic arsenal?. Heart Rhythm, 2015, 12, 1080-1087.	0.7	9
116	Inter–Core Lab Variability in Analyzing Quantitative Coronary Angiography forÂBifurcation Lesions. JACC: Cardiovascular Interventions, 2015, 8, 305-314.	2.9	31
117	Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: AÂpathology study. Atherosclerosis, 2015, 241, 772-782.	0.8	151
118	Distal Embolization of Hydrophilic-Coating Material From Coronary Guidewires After Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2015, 8, e001816.	3.9	50
119	Comparative Effectiveness of Hybrid Coronary Revascularization vs Coronary Artery Bypass Grafting. Journal of the American College of Surgeons, 2015, 221, 326-334e1.	0.5	48
120	Cathether-based interventional strategies for cor triatriatum in the adult $\hat{a} \in \text{``feasibility study through a hybrid approach. BMC Cardiovascular Disorders, 2015, 15, 68.}$	1.7	16
121	Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. PLoS ONE, 2015, 10, e0122836.	2.5	6
122	Stents Eluting 6-Mercaptopurine Reduce Neointima Formation and Inflammation while Enhancing Strut Coverage in Rabbits. PLoS ONE, 2015, 10, e0138459.	2.5	7
123	Cardiac troponin release following hybrid coronary revascularization versus off-pump coronary artery bypass surgery. Interactive Cardiovascular and Thoracic Surgery, 2014, 19, 1008-1012.	1.1	10
124	Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. Heart, 2014, 100, 951-959.	2.9	102
125	Standardizing definitions for hybrid coronary revascularization. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 556-560.	0.8	36
126	The Prognostic Value of Bleeding Academic Research Consortium (BARC)-Defined BleedingÂComplications in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1866-1875.	2.8	93

#	Article	IF	CITATIONS
127	Impact of an invasive strategy on 5 years outcome in men and women with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2014, 168, 522-529.	2.7	16
128	Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity. Circulation: Cardiovascular Interventions, 2014, 7, 301-311.	3.9	322
129	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	1.6	25
130	Hospital patterns of medical management strategy use for patients with non–ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. American Heart Journal, 2014, 167, 355-362.e3.	2.7	11
131	Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery. Annals of Thoracic Surgery, 2014, 97, 824-830.	1.3	13
132	The relationship between the number of preprocedural circulating endothelial progenitor cells and angiographic restenosis following coronary artery stent placement. Heart Asia, 2011, 3, 60-5.	1.1	0
133	Metabolic Background Determines the Importance of NOS3Polymorphisms in Restenosis after Percutaneous Coronary Intervention: A Study in Patients with and without the Metabolic Syndrome. Disease Markers, 2009, 26, 75-83.	1.3	6
134	Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. American Journal of Cardiology, 2004, 94, 1481-1485.	1.6	26
135	C-reactive protein and coronary events following percutaneous coronary angioplasty. American Journal of Medicine, 2003, 115, 85-90.	1.5	58
136	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ^{2} > A mutation., 1998, 44, 427-430.		1
137	Immediate and Long-Term Effect of Balloon Angioplasty or Stent Implantation on the Absolute and Relative Coronary Blood Flow Velocity Reserve. Circulation, 1998, 98, 2133-2140.	1.6	91
138	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ ⁻² > A mutation. Catheterization and Cardiovascular Diagnosis, 1998, 44, 427-430.	0.3	1
139	Critical difference between serial measurements of CK-MB mass to detect myocardial damage. Clinical Chemistry, 1997, 43, 338-343.	3.2	20
140	Angioplasty of chronic total coronary occlusions with the use of six French guiding catheters. , 1997, 40, 255-260.		4
141	Pressure recordings in coexistent fixed congenital membraneous and hypertrophic subaortic stenosis. Catheterization and Cardiovascular Diagnosis, 1995, 36, 262-264.	0.3	0
142	Value of Myoglobin, Troponin T, and CK-MB _{mass} in Ruling Out an Acute Myocardial Infarction in the Emergency Room. Circulation, 1995, 92, 3401-3407.	1.6	263